Genome-editing technologies for gene and cell therapy

Molecular Therapy

Volumn 24, Issue 3, 2016, Pages 430-446

  Maeder, Morgan L ^a   Gersbach, Charles A ^b,c,d  

^a EDITAS MEDICINE   (United States)

^b USA   (United States)

^c DUKE UNIVERSITY   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; MEGANUCLEASE; NUCLEASE; TRANSCRIPTION ACTIVATOR LIKE EFFECTOR NUCLEASE; UNCLASSIFIED DRUG; ZINC FINGER NUCLEASE; ENDONUCLEASE;

AMYOTROPHIC LATERAL SCLEROSIS; BETA THALASSEMIA; CANCER IMMUNOTHERAPY; CELL THERAPY; CYSTIC FIBROSIS; DUCHENNE MUSCULAR DYSTROPHY; ENZYME SPECIFICITY; EPIDERMOLYSIS BULLOSA DYSTROPHICA; FRIEDREICH ATAXIA; GENE CORRECTION; GENE DELETION; GENE INSERTION; GENE THERAPY; GENETIC PARAMETERS; GENOME EDITING; HUMAN; HUNTINGTON CHOREA; LEBER CONGENITAL AMAUROSIS; LIMB GIRDLE MUSCULAR DYSTROPHY; MOLECULAR GENETICS; MUTATIONAL ANALYSIS; NONHUMAN; NONVIRAL GENE THERAPY; REVIEW; SICKLE CELL ANEMIA; SPINAL MUSCULAR ATROPHY; STRUCTURE ANALYSIS; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; ANIMAL; BIOLOGICAL THERAPY; GENE EDITING; GENE TARGETING; GENE TRANSFER; GENE VECTOR; GENETICS; GENOME; METABOLISM; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRECLINICAL STUDY; PROCEDURES;

ANIMALS; CELL- AND TISSUE-BASED THERAPY; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; DRUG EVALUATION, PRECLINICAL; ENDONUCLEASES; GENE EDITING; GENE TARGETING; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; GENOME; HUMANS;

EID: 84960431733     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2016.10     Document Type: Review

References (297)

1. Friedmann, T and Roblin, R. (1972). Gene therapy for human genetic disease?. Science 175: 949-955
2. Naldini, L. (2015). Gene therapy returns to centre stage. Nature 526: 351-360
3. Baum, C, von Kalle, C, Staal, FJ, Li, Z, Fehse, B, Schmidt, M, et al. (2004). Chance or necessity?. Insertional mutagenesis in gene therapy and its consequences. Mol Ther 9: 5-13
4. Takata, M, Sasaki, MS, Sonoda, E, Morrison, C, Hashimoto, M, Utsumi, H, et al. (1998). Homologous recombination and non-homologous end-joining pathways of DNA double-strand break repair have overlapping roles in the maintenance of chromosomal integrity in vertebrate cells. EMBO J 17: 5497-5508
5. Szostak, JW, Orr-Weaver, TL, Rothstein, RJ and Stahl, FW. (1983). The double-strandbreak repair model for recombination. Cell 33: 25-35
6. Rouet, P, Smih, F and Jasin, M. (1994). Expression of a site-specific endonuclease stimulates homologous recombination in mammalian cells. Proc Natl Acad Sci USA 91: 6064-6068
7. Smih, F, Rouet, P, Romanienko, PJ and Jasin, M. (1995). Double-strand breaks at the target locus stimulate gene targeting in embryonic stem cells. Nucleic Acids Res 23: 5012-5019
8. Choulika, A, Perrin, A, Dujon, B and Nicolas, JF. (1995). Induction of homologous recombination in mammalian chromosomes by using the I-SceI system of Saccharomyces cerevisiae. Mol Cell Biol 15: 1968-1973
9. Lieber, MR, Ma, Y, Pannicke, U and Schwarz, K. (2003). Mechanism and regulation of human non-homologous DNA end-joining. Nat Rev Mol Cell Biol 4: 712-720
10. Bibikova, M, Golic, M, Golic, KG and Carroll, D. (2002). Targeted chromosomal cleavage and mutagenesis in Drosophila using zinc-finger nucleases. Genetics 161: 1169-1175
11. Santiago, Y, Chan, E, Liu, PQ, Orlando, S, Zhang, L, Urnov, FD, et al. (2008). Targeted gene knockout in mammalian cells by using engineered zinc-finger nucleases. Proc Natl Acad Sci USA 105: 5809-5814
12. Geurts, AM, Cost, GJ, Freyvert, Y, Zeitler, B, Miller, JC, Choi, VM, et al. (2009). Knockout rats via embryo microinjection of zinc-finger nucleases. Science 325: 433
13. Doyon, Y, McCammon, JM, Miller, JC, Faraji, F, Ngo, C, Katibah, GE, et al. (2008). Heritable targeted gene disruption in zebrafish using designed zinc-finger nucleases. Nat Biotechnol 26: 702-708
14. Meng, X, Noyes, MB, Zhu, LJ, Lawson, ND and Wolfe, SA. (2008). Targeted gene inactivation in zebrafish using engineered zinc-finger nucleases. Nat Biotechnol 26: 695-701
15. Ciccia, A and Elledge, SJ. (2010). The DNA damage response: making it safe to play with knives. Mol Cell 40: 179-204
16. Chapman, JR, Taylor, MR and Boulton, SJ. (2012). Playing the end game: DNA double-strand break repair pathway choice. Mol Cell 47: 497-510
17. Ousterout, DG, Perez-Pinera, P, Thakore, PI, Kabadi, AM, Brown, MT, Qin, X, et al. (2013). Reading frame correction by targeted genome editing restores dystrophin expression in cells from Duchenne muscular dystrophy patients. Mol Ther 21: 1718-1726
18. Aronin, N and DiFiglia, M. (2014). Huntingtin-lowering strategies in Huntingtons disease: antisense oligonucleotides, small RNAs and gene editing. Mov Disord 29: 1455-1461
19. Ramaswamy, S and Kordower, JH. (2012). Gene therapy for Huntingtons disease. Neurobiol Dis 48: 243-254
20. Perez, EE, Wang, J, Miller, JC, Jouvenot, Y, Kim, KA, Liu, O, et al. (2008). Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat Biotechnol 26: 808-816
21. Holt, N, Wang, J, Kim, K, Friedman, G, Wang, X, Taupin, V, et al. (2010). Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat Biotechnol 28: 839-847
22. Tebas, P, Stein, D, Tang, WW, Frank, I, Wang, SQ, Lee, G, et al. (2014). Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med 370: 901-910
23. Kennedy, EM and Cullen, BR. (2015). Bacterial CRISPR/Cas DNA endonucleases: A revolutionary technology that could dramatically impact viral research and treatment. Virology 479-480: 213-220
24. Beisel, CL, Gomaa, AA and Barrangou, R. (2014). A CRISPR design for next-generation antimicrobials. Genome Biol 15: 516
25. Lee, HJ, Kim, E and Kim, JS. (2010). Targeted chromosomal deletions in human cells using zinc finger nucleases. Genome Res 20: 81-89
26. Gupta, A, Hall, VL, Kok, FO, Shin, M, McNulty, JC, Lawson, ND, et al. (2013). Targeted chromosomal deletions and inversions in zebrafish. Genome Res 23: 1008-1017
27. Xiao, A, Wang, Z, Hu, Y, Wu, Y, Luo, Z, Yang, Z, et al. (2013). Chromosomal deletions and inversions mediated by TALENs and CRISPR/Cas in zebrafish. Nucleic Acids Res 41: e141
28. Canver, MC, Bauer, DE, Dass, A, Yien, YY, Chung, J, Masuda, T, et al. (2014). Characterization of genomic deletion efficiency mediated by clustered regularly interspaced palindromic repeats (CRISPR)/Cas9 nuclease system in mammalian cells. J Biol Chem 289: 21312-21324
29. Söllü, C, Pars, K, Cornu, TI, Thibodeau-Beganny, S, Maeder, ML, Joung, JK, et al. (2010). Autonomous zinc-finger nuclease pairs for targeted chromosomal deletion. Nucleic Acids Res 38: 8269-8276
30. Bauer, DE, Kamran, SC, Lessard, S, Xu, J, Fujiwara, Y, Lin, C, et al. (2013). An erythroid enhancer of BCL11A subject to genetic variation determines fetal hemoglobin level. Science 342: 253-257
31. Canver, MC, Smith, EC, Sher, F, Pinello, L, Sanjana, NE, Shalem, O, et al. (2015). BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis. Nature 527: 192-197
32. Ousterout, DG, Kabadi, AM, Thakore, PI, Perez-Pinera, P, Brown, MT, Majoros, WH, et al. (2015). Correction of dystrophin expression in cells from Duchenne muscular dystrophy patients through genomic excision of exon 51 by zinc finger nucleases. Mol Ther 23: 523-532
33. Ousterout, DG, Kabadi, AM, Thakore, PI, Majoros, WH, Reddy, TE and Gersbach, CA. (2015). Multiplex CRISPR/Cas9-based genome editing for correction of dystrophin mutations that cause Duchenne muscular dystrophy. Nat Commun 6: 6244
34. Li, HL, Fujimoto, N, Sasakawa, N, Shirai, S, Ohkame, T, Sakuma, T, et al. (2015). Precise correction of the dystrophin gene in duchenne muscular dystrophy patient induced pluripotent stem cells by TALEN and CRISPR-Cas9. Stem Cell Reports 4: 143-154
35. Nelson, CE, Hakim, CH, Ousterout, DG, Thakore, PI, Moreb, EA, Rivera, RM, et al. (2016). In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. Science 351: 403-407
36. Tabebordbar, M, Zhu, K, Cheng, JK, Chew, WL, Widrick, JJ, Yan, WX, et al. (2016). In vivo gene editing in dystrophic mouse muscle and muscle stem cells. Science 351: 407-411
37. Long, C, Amoasii, L, Mireault, AA, McAnally, JR, Li, H, Sanchez-Ortiz, E, et al. (2016). Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy. Science 351: 400-403
38. Heyer, WD, Ehmsen, KT and Liu, J. (2010). Regulation of homologous recombination in eukaryotes. Annu Rev Genet 44: 113-139
39. Thomas, KR and Capecchi, MR. (1987). Site-directed mutagenesis by gene targeting in mouse embryo-derived stem cells. Cell 51: 503-512
40. Urnov, FD, Miller, JC, Lee, YL, Beausejour, CM, Rock, JM, Augustus, S, et al. (2005). Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature 435: 646-651
41. Long, C, McAnally, JR, Shelton, JM, Mireault, AA, Bassel-Duby, R and Olson, EN. (2014). Prevention of muscular dystrophy in mice by CRISPR/Cas9-mediated editing of germline DNA. Science 345: 1184-1188
42. Sebastiano, V, Maeder, ML, Angstman, JF, Haddad, B, Khayter, C, Yeo, DT, et al. (2011). In situ genetic correction of the sickle cell anemia mutation in human induced pluripotent stem cells using engineered zinc finger nucleases. Stem Cells 29: 1717-1726
43. Zou, J, Mali, P, Huang, X, Dowey, SN and Cheng, L. (2011). Site-specific gene correction of a point mutation in human iPS cells derived from an adult patient with sickle cell disease. Blood 118: 4599-4608
44. Soldner, F, Laganière, J, Cheng, AW, Hockemeyer, D, Gao, Q, Alagappan, R, et al. (2011). Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations. Cell 146: 318-331
45. Yusa, K, Rashid, ST, Strick-Marchand, H, Varela, I, Liu, PQ, Paschon, DE, et al. (2011). Targeted gene correction of 1-Antitrypsin deficiency in induced pluripotent stem cells. Nature 478: 391-394
46. Low, BE, Krebs, MP, Joung, JK, Tsai, SQ, Nishina, PM and Wiles, MV. (2014). Correction of the Crb1rd8 allele and retinal phenotype in C57BL/6N mice via TALEN-mediated homology-directed repair. Invest Ophthalmol Vis Sci 55: 387-395
47. Sanders, LH, Laganière, J, Cooper, O, Mak, SK, Vu, BJ, Huang, YA, et al. (2014). LRRK2 mutations cause mitochondrial DNA damage in iPSC-derived neural cells from Parkinsons disease patients: reversal by gene correction. Neurobiol Dis 62: 381-386
48. Xie, F, Ye, L, Chang, JC, Beyer, AI, Wang, J, Muench, MO, et al. (2014). Seamless gene correction of-Thalassemia mutations in patient-specific iPSCs using CRISPR/Cas9 and piggyBac. Genome Res 24: 1526-1533
49. Wu, Y, Liang, D, Wang, Y, Bai, M, Tang, W, Bao, S, et al. (2013). Correction of a genetic disease in mouse via use of CRISPR-Cas9. Cell Stem Cell 13: 659-662
50. Schwank, G, Koo, BK, Sasselli, V, Dekkers, JF, Heo, I, Demircan, T, et al. (2013). Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. Cell Stem Cell 13: 653-658
51. Chen, F, Pruett-Miller, SM, Huang, Y, Gjoka, M, Duda, K, Taunton, J, et al. (2011). High-frequency genome editing using ssDNA oligonucleotides with zinc-finger nucleases. Nat Methods 8: 753-755
52. Bedell, VM, Wang, Y, Campbell, JM, Poshusta, TL, Starker, CG, Krug, RG 2nd, et al. (2012). In vivo genome editing using a high-efficiency TALEN system. Nature 491: 114-118
53. Ding, Q, Lee, YK, Schaefer, EA, Peters, DT, Veres, A, Kim, K, et al. (2013). A TALEN genome-editing system for generating human stem cell-based disease models. Cell Stem Cell 12: 238-251
54. Händel, EM, Gellhaus, K, Khan, K, Bednarski, C, Cornu, TI, Müller-Lerch, F, et al. (2012). Versatile and efficient genome editing in human cells by combining zincfinger nucleases with adeno-Associated viral vectors. Hum Gene Ther 23: 321-329
55. Coluccio, A, Miselli, F, Lombardo, A, Marconi, A, Malagoli Tagliazucchi, G, Gonçalves, MA, et al. (2013). Targeted gene addition in human epithelial stem cells by zinc-finger nuclease-mediated homologous recombination. Mol Ther 21: 1695-1704
56. Hirsch, ML, Green, L, Porteus, MH and Samulski, RJ. (2010). Self-complementary AAV mediates gene targeting and enhances endonuclease delivery for double-strand break repair. Gene Ther 17: 1175-1180
57. Genovese, P, Schiroli, G, Escobar, G, Di Tomaso, T, Firrito, C, Calabria, A, et al. (2014). Targeted genome editing in human repopulating haematopoietic stem cells. Nature 510: 235-240
58. Miller, DG, Wang, PR, Petek, LM, Hirata, RK, Sands, MS and Russell, DW. (2006). Gene targeting in vivo by adeno-Associated virus vectors. Nat Biotechnol 24: 1022-1026
59. Grimm, D, Lee, JS, Wang, L, Desai, T, Akache, B, Storm, TA, et al. (2008). In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-Associated viruses. J Virol 82: 5887-5911
60. Melo, SP, Lisowski, L, Bashkirova, E, Zhen, HH, Chu, K, Keene, DR, et al. (2014). Somatic correction of junctional epidermolysis bullosa by a highly recombinogenic AAV variant. Mol Ther 22: 725-733
61. Porteus, MH, Cathomen, T, Weitzman, MD and Baltimore, D. (2003). Efficient gene targeting mediated by adeno-Associated virus and DNA double-strand breaks. Mol Cell Biol 23: 3558-3565
62. Asuri, P, Bartel, MA, Vazin, T, Jang, JH, Wong, TB and Schaffer, DV. (2012). Directed evolution of adeno-Associated virus for enhanced gene delivery and gene targeting in human pluripotent stem cells. Mol Ther 20: 329-338
63. Hacein-Bey-Abina, S, Von Kalle, C, Schmidt, M, McCormack, MP, Wulffraat, N, Leboulch, P, et al. (2003). LMO2-Associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302: 415-419
64. Baum, C, Kustikova, O, Modlich, U, Li, Z and Fehse, B. (2006). Mutagenesis and oncogenesis by chromosomal insertion of gene transfer vectors. Hum Gene Ther 17: 253-263
65. Baum, C, Modlich, U, Göhring, G and Schlegelberger, B. (2011). Concise review: managing genotoxicity in the therapeutic modification of stem cells. Stem Cells 29: 1479-1484
66. Moehle, EA, Moehle, EA, Rock, JM, Rock, JM, Lee, YL, Lee, YL, et al. (2007). Targeted gene addition into a specified location in the human genome using designed zinc finger nucleases. Proc Natl Acad Sci USA 104: 3055-3060
67. Lombardo, A, Cesana, D, Genovese, P, Di Stefano, B, Provasi, E, Colombo, DF, et al. (2011). Site-specific integration and tailoring of cassette design for sustainable gene transfer. Nat Methods 8: 861-869
68. Zou, J, Sweeney, CL, Chou, BK, Choi, U, Pan, J, Wang, H, et al. (2011). Oxidasedeficient neutrophils from X-linked chronic granulomatous disease iPS cells: functional correction by zinc finger nuclease-mediated safe harbor targeting. Blood 117: 5561-5572
69. Chang, CJ and Bouhassira, EE. (2012). Zinc-finger nuclease-mediated correction of-Thalassemia in iPS cells. Blood 120: 3906-3914
70. Li, H, Haurigot, V, Doyon, Y, Li, T, Wong, SY, Bhagwat, AS, et al. (2011). In vivo genome editing restores haemostasis in a mouse model of haemophilia. Nature 475: 217-221
71. Barzel, A, Paulk, NK, Shi, Y, Huang, Y, Chu, K, Zhang, F, et al. (2015). Promoterless gene targeting without nucleases ameliorates haemophilia B in mice. Nature 517: 360-364
72. Maresca, M, Lin, VG, Guo, N and Yang, Y. (2013). Obligate ligation-gated recombination (ObLiGaRe): custom-designed nuclease-mediated targeted integration through nonhomologous end joining. Genome Res 23: 539-546
73. Tupler, R, Perini, G and Green, MR. (2001). Expressing the human genome. Nature 409: 832-833
74. Pavletich, NP and Pabo, CO. (1991). Zinc finger-DNA recognition: crystal structure of a Zif268-DNA complex at 2.1 A. Science 252: 809-817
75. Elrod-Erickson, M, Rould, MA, Nekludova, L and Pabo, CO. (1996). Zif268 protein-DNA complex refined at 1.6 A: a model system for understanding zinc finger-DNA interactions. Structure 4: 1171-1180
76. Elrod-Erickson, M, Benson, TE and Pabo, CO. (1998). High-resolution structures of variant Zif268-DNA complexes: implications for understanding zinc finger-DNA recognition. Structure 6: 451-464
77. Lee, MS, Gippert, GP, Soman, KV, Case, DA and Wright, PE. (1989). Three-dimensional solution structure of a single zinc finger DNA-binding domain. Science 245: 635-637
78. Pabo, CO, Peisach, E and Grant, RA. (2001). Design and selection of novel Cys2His2 zinc finger proteins. Annu Rev Biochem 70: 313-340
79. Gersbach, CA, Gaj, T and Barbas, CF 3rd. (2014). Synthetic zinc finger proteins: the advent of targeted gene regulation and genome modification technologies. Acc Chem Res 47: 2309-2318
80. Desjarlais, JR and Berg, JM. (1992). Toward rules relating zinc finger protein sequences and DNA binding site preferences. Proc Natl Acad Sci USA 89: 7345-7349
81. Desjarlais, JR and Berg, JM. (1992). Redesigning the DNA-binding specificity of a zinc finger protein: a data base-guided approach. Proteins 12: 101-104
82. Rebar, EJ and Pabo, CO. (1994). Zinc finger phage: affinity selection of fingers with new DNA-binding specificities. Science 263: 671-673
83. Choo, Y and Klug, A. (1994). Toward a code for the interactions of zinc fingers with DNA: selection of randomized fingers displayed on phage. Proc Natl Acad Sci USA 91: 11163-11167
84. Jamieson, AC, Kim, SH and Wells, JA. (1994). In vitro selection of zinc fingers with altered DNA-binding specificity. Biochemistry 33: 5689-5695
85. Wu, H, Yang, WP and Barbas, CF 3rd. (1995). Building zinc fingers by selection: toward a therapeutic application. Proc Natl Acad Sci USA 92: 344-348
86. Joung, JK, Ramm, EI and Pabo, CO. (2000). A bacterial two-hybrid selection system for studying protein-DNA and protein-protein interactions. Proc Natl Acad Sci USA 97: 7382-7387
87. Blancafort, P, Magnenat, L and Barbas, CF 3rd. (2003). Scanning the human genome with combinatorial transcription factor libraries. Nat Biotechnol 21: 269-274
88. Bae, KH, Kwon, YD, Shin, HC, Hwang, MS, Ryu, EH, Park, KS, et al. (2003). Human zinc fingers as building blocks in the construction of artificial transcription factors. Nat Biotechnol 21: 275-280
89. Segal, DJ, Dreier, B, Beerli, RR and Barbas, CF 3rd. (1999). Toward controlling gene expression at will: selection and design of zinc finger domains recognizing each of the 5-GNN-3 DNA target sequences. Proc Natl Acad Sci USA 96: 2758-2763
90. Dreier, B, Beerli, RR, Segal, DJ, Flippin, JD and Barbas, CF 3rd. (2001). Development of zinc finger domains for recognition of the 5-ANN-3 family of DNA sequences and their use in the construction of artificial transcription factors. J Biol Chem 276: 29466-29478
91. Dreier, B, Fuller, RP, Segal, DJ, Lund, CV, Blancafort, P, Huber, A, et al. (2005). Development of zinc finger domains for recognition of the 5-CNN-3 family DNA sequences and their use in the construction of artificial transcription factors. J Biol Chem 280: 35588-35597
92. Liu, Q, Xia, Z, Zhong, X and Case, CC. (2002). Validated zinc finger protein designs for all 16 GNN DNA triplet targets. J Biol Chem 277: 3850-3856
93. Beerli, RR, Segal, DJ, Dreier, B and Barbas, CF 3rd. (1998). Toward controlling gene expression at will: specific regulation of the erbB-2/HER-2 promoter by using polydactyl zinc finger proteins constructed from modular building blocks. Proc Natl Acad Sci USA 95: 14628-14633
94. Beerli, RR, Dreier, B and Barbas, CF 3rd. (2000). Positive and negative regulation of endogenous genes by designed transcription factors. Proc Natl Acad Sci USA 97: 1495-1500
95. Kim, S, Lee, MJ, Kim, H, Kang, M and Kim, JS. (2011). Preassembled zinc-finger arrays for rapid construction of ZFNs. Nat Methods 8: 7
96. Bhakta, MS, Henry, IM, Ousterout, DG, Das, KT, Lockwood, SH, Meckler, JF, et al. (2013). Highly active zinc-finger nucleases by extended modular assembly. Genome Res 23: 530-538
97. Gonzalez, B, Schwimmer, LJ, Fuller, RP, Ye, Y, Asawapornmongkol, L and Barbas, CF 3rd. (2010). Modular system for the construction of zinc-finger libraries and proteins. Nat Protoc 5: 791-810
98. Maeder, ML, Thibodeau-Beganny, S, Osiak, A, Wright, DA, Anthony, RM, Eichtinger, M, et al. (2008). Rapid open-source engineering of customized zincfinger nucleases for highly efficient gene modification. Mol Cell 31: 294-301
99. Wolfe, SA, Greisman, HA, Ramm, EI and Pabo, CO. (1999). Analysis of zinc fingers optimized via phage display: evaluating the utility of a recognition code. J Mol Biol 285: 1917-1934
100. Isalan, M, Choo, Y and Klug, A. (1997). Synergy between adjacent zinc fingers in sequence-specific DNA recognition. Proc Natl Acad Sci USA 94: 5617-5621
101. Isalan, M, Klug, A and Choo, Y. (1998). Comprehensive DNA recognition through concerted interactions from adjacent zinc fingers. Biochemistry 37: 12026-12033
102. Sander, JD, Dahlborg, EJ, Goodwin, MJ, Cade, L, Zhang, F, Cifuentes, D, et al. (2011). Selection-free zinc-finger-nuclease engineering by context-dependent assembly (CoDA). Nat Methods 8: 67-69
103. Gupta, A, Christensen, RG, Rayla, AL, Lakshmanan, A, Stormo, GD and Wolfe, SA. (2012). An optimized two-finger archive for ZFN-mediated gene targeting. Nat Methods 9: 588-590
104. Isalan, M, Klug, A and Choo, Y. (2001). A rapid, generally applicable method to engineer zinc fingers illustrated by targeting the HIV-1 promoter. Nat Biotechnol 19: 656-660
105. Li, L, Wu, LP and Chandrasegaran, S. (1992). Functional domains in Fok I restriction endonuclease. Proc Natl Acad Sci USA 89: 4275-4279
106. Kim, YG and Chandrasegaran, S. (1994). Chimeric restriction endonuclease. Proc Natl Acad Sci USA 91: 883-887
107. Kim, YG, Cha, J and Chandrasegaran, S. (1996). Hybrid restriction enzymes: zinc finger fusions to Fok I cleavage domain. Proc Natl Acad Sci USA 93: 1156-1160
108. Smith, J, Bibikova, M, Whitby, FG, Reddy, AR, Chandrasegaran, S and Carroll, D. (2000). Requirements for double-strand cleavage by chimeric restriction enzymes with zinc finger DNA-recognition domains. Nucleic Acids Res 28: 3361-3369
109. Bibikova, M, Carroll, D, Segal, DJ, Trautman, JK, Smith, J, Kim, YG, et al. (2001). Stimulation of homologous recombination through targeted cleavage by chimeric nucleases. Mol Cell Biol 21: 289-297
110. Porteus, MH and Baltimore, D. (2003). Chimeric nucleases stimulate gene targeting in human cells. Science 300: 763
111. Lombardo, A, Genovese, P, Beausejour, CM, Colleoni, S, Lee, YL, Kim, KA, et al. (2007). Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery. Nat Biotechnol 25: 1298-1306
112. Zou, J, Maeder, ML, Mali, P, Pruett-Miller, SM, Thibodeau-Beganny, S, Chou, BK, et al. (2009). Gene targeting of a disease-related gene in human induced pluripotent stem and embryonic stem cells. Cell Stem Cell 5: 97-110
113. Hockemeyer, D, Soldner, F, Beard, C, Gao, Q, Mitalipova, M, DeKelver, RC, et al. (2009). Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-finger nucleases. Nat Biotechnol 27: 851-857
114. Boch, J, Scholze, H, Schornack, S, Landgraf, A, Hahn, S, Kay, S, et al. (2009). Breaking the code of DNA binding specificity of TAL-Type III effectors. Science 326: 1509-1512
115. Moscou, MJ and Bogdanove, AJ. (2009). A simple cipher governs DNA recognition by TAL effectors. Science 326: 1501
116. Deng, D, Yan, C, Pan, X, Mahfouz, M, Wang, J, Zhu, JK, et al. (2012). Structural basis for sequence-specific recognition of DNA by TAL effectors. Science 335: 720-723
117. Mak, AN, Bradley, P, Cernadas, RA, Bogdanove, AJ and Stoddard, BL. (2012). The crystal structure of TAL effector PthXo1 bound to its DNA target. Science 335: 716-719
118. Morbitzer, R, Römer, P, Boch, J and Lahaye, T. (2010). Regulation of selected genome loci using de novo-engineered transcription activator-like effector (TALE)-Type transcription factors. Proc Natl Acad Sci USA 107: 21617-21622
119. Miller, JC, Tan, S, Qiao, G, Barlow, KA, Wang, J, Xia, DF, et al. (2011). A TALE nuclease architecture for efficient genome editing. Nat Biotechnol 29: 143-148
120. Zhang, F, Cong, L, Lodato, S, Kosuri, S, Church, GM and Arlotta, P. (2011). Efficient construction of sequence-specific TAL effectors for modulating mammalian transcription. Nat Biotechnol 29: 149-153
121. Christian, M, Cermak, T, Doyle, EL, Schmidt, C, Zhang, F, Hummel, A, et al. (2010). Targeting DNA double-strand breaks with TAL effector nucleases. Genetics 186: 757-761
122. Li, T, Huang, S, Jiang, WZ, Wright, D, Spalding, MH, Weeks, DP, et al. (2011). TAL nucleases (TALNs): hybrid proteins composed of TAL effectors and FokI DNA-cleavage domain. Nucleic Acids Res 39: 359-372
123. Sander, JD, Cade, L, Khayter, C, Reyon, D, Peterson, RT, Joung, JK, et al. (2011). Targeted gene disruption in somatic zebrafish cells using engineered TALENs. Nat Biotechnol 29: 697-698
124. Huang, P, Xiao, A, Zhou, M, Zhu, Z, Lin, S and Zhang, B. (2011). Heritable gene targeting in zebrafish using customized TALENs. Nat Biotechnol 29: 699-700
125. Morbitzer, R, Elsaesser, J, Hausner, J and Lahaye, T. (2011). Assembly of custom TALEtype DNA binding domains by modular cloning. Nucleic Acids Res 39: 5790-5799
126. Cermak, T, Doyle, EL, Christian, M, Wang, L, Zhang, Y, Schmidt, C, et al. (2011). Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting. Nucleic Acids Res 39: e82
127. Li, L, Piatek, MJ, Atef, A, Piatek, A, Wibowo, A, Fang, X, et al. (2012). Rapid and highly efficient construction of TALE-based transcriptional regulators and nucleases for genome modification. Plant Mol Biol 78: 407-416
128. Weber, E, Gruetzner, R, Werner, S, Engler, C and Marillonnet, S. (2011). Assembly of designer TAL effectors by Golden Gate cloning. PLoS One 6: e19722
129. Sanjana, NE, Cong, L, Zhou, Y, Cunniff, MM, Feng, G and Zhang, F. (2012). A transcription activator-like effector toolbox for genome engineering. Nat Protoc 7: 171-192
130. Briggs, AW, Rios, X, Chari, R, Yang, L, Zhang, F, Mali, P, et al. (2012). Iterative capped assembly: rapid and scalable synthesis of repeat-module DNA such as TAL effectors from individual monomers. Nucleic Acids Res 40: e117
131. Wang, Z, Li, J, Huang, H, Wang, G, Jiang, M, Yin, S, et al. (2012). An integrated chip for the high-Throughput synthesis of transcription activator-like effectors. Angew Chem Int Ed Engl 51: 8505-8508
132. Reyon, D, Tsai, SQ, Khayter, C, Foden, JA, Sander, JD and Joung, JK. (2012). FLASH assembly of TALENs for high-Throughput genome editing. Nat Biotechnol 30: 460-465
133. Schmid-Burgk, JL, Schmidt, T, Kaiser, V, Höning, K and Hornung, V. (2013). A ligationindependent cloning technique for high-Throughput assembly of transcription activator-like effector genes. Nat Biotechnol 31: 76-81
134. Mussolino, C, Morbitzer, R, Lütge, F, Dannemann, N, Lahaye, T and Cathomen, T. (2011). A novel TALE nuclease scaffold enables high genome editing activity in combination with low toxicity. Nucleic Acids Res 39: 9283-9293
135. Li, T, Huang, S, Zhao, X, Wright, DA, Carpenter, S, Spalding, MH, et al. (2011). Modularly assembled designer TAL effector nucleases for targeted gene knockout and gene replacement in eukaryotes. Nucleic Acids Res 39: 6315-6325
136. Hockemeyer, D, Wang, H, Kiani, S, Lai, CS, Gao, Q, Cassady, JP, et al. (2011). Genetic engineering of human pluripotent cells using TALE nucleases. Nat Biotechnol 29: 731-734
137. Holkers, M, Maggio, I, Liu, J, Janssen, JM, Miselli, F, Mussolino, C, et al. (2013). Differential integrity of TALE nuclease genes following adenoviral and lentiviral vector gene transfer into human cells. Nucleic Acids Res 41: e63
138. Yang, L, Guell, M, Byrne, S, Yang, JL, De Los Angeles, A, Mali, P, et al. (2013). Optimization of scarless human stem cell genome editing. Nucleic Acids Res 41: 9049-9061
139. Holkers, M, Maggio, I, Henriques, SF, Janssen, JM, Cathomen, T and Gonçalves, MA. (2014). Adenoviral vector DNA for accurate genome editing with engineered nucleases. Nat Methods 11: 1051-1057
140. Chevalier, BS and Stoddard, BL. (2001). Homing endonucleases: structural and functional insight into the catalysts of intron/intein mobility. Nucleic Acids Res 29: 3757-3774
141. Redondo, P, Prieto, J, Muñoz, IG, Alibés, A, Stricher, F, Serrano, L, et al. (2008). Molecular basis of xeroderma pigmentosum group C DNA recognition by engineered meganucleases. Nature 456: 107-111
142. Grizot, S, Smith, J, Daboussi, F, Prieto, J, Redondo, P, Merino, N, et al. (2009). Efficient targeting of a SCID gene by an engineered single-chain homing endonuclease. Nucleic Acids Res 37: 5405-5419
143. Seligman, LM, Chisholm, KM, Chevalier, BS, Chadsey, MS, Edwards, ST, Savage, JH, et al. (2002). Mutations altering the cleavage specificity of a homing endonuclease. Nucleic Acids Res 30: 3870-3879
144. Sussman, D, Chadsey, M, Fauce, S, Engel, A, Bruett, A, Monnat, R Jr, et al. (2004). Isolation and characterization of new homing endonuclease specificities at individual target site positions. J Mol Biol 342: 31-41
145. Rosen, LE, Morrison, HA, Masri, S, Brown, MJ, Springstubb, B, Sussman, D, et al. (2006). Homing endonuclease I-CreI derivatives with novel DNA target specificities. Nucleic Acids Res 34: 4791-4800
146. Smith, J, Grizot, S, Arnould, S, Duclert, A, Epinat, JC, Chames, P, et al. (2006). A combinatorial approach to create artificial homing endonucleases cleaving chosen sequences. Nucleic Acids Res 34: e149
147. Chevalier, BS, Kortemme, T, Chadsey, MS, Baker, D, Monnat, RJ and Stoddard, BL. (2002). Design, activity and structure of a highly specific artificial endonuclease. Mol Cell 10: 895-905
148. Arnould, S, Perez, C, Cabaniols, JP, Smith, J, Gouble, A, Grizot, S, et al. (2007). Engineered I-CreI derivatives cleaving sequences from the human XPC gene can induce highly efficient gene correction in mammalian cells. J Mol Biol 371: 49-65
149. Gürlevik, E, Schache, P, Goez, A, Kloos, A, Woller, N, Armbrecht, N, et al. (2013). Meganuclease-mediated virus self-cleavage facilitates tumor-specific virus replication. Mol Ther 21: 1738-1748
150. Dupuy, A, Valton, J, Leduc, S, Armier, J, Galetto, R, Gouble, A, et al. (2013). Targeted gene therapy of xeroderma pigmentosum cells using meganuclease and TALEN™. PLoS One 8: e78678
151. Rivière, J, Hauer, J, Poirot, L, Brochet, J, Souque, P, Mollier, K, et al. (2014). Variable correction of Artemis deficiency by I-Sce1-meganuclease-Assisted homologous recombination in murine hematopoietic stem cells. Gene Ther 21: 529-532
152. Gao, H, Smith, J, Yang, M, Jones, S, Djukanovic, V, Nicholson, MG, et al. (2010). Heritable targeted mutagenesis in maize using a designed endonuclease. Plant J 61: 176-187
153. Kleinstiver, BP, Wolfs, JM, Kolaczyk, T, Roberts, AK, Hu, SX and Edgell, DR. (2012). Monomeric site-specific nucleases for genome editing. Proc Natl Acad Sci USA 109: 8061-8066
154. Boissel, S, Jarjour, J, Astrakhan, A, Adey, A, Gouble, A, Duchateau, P, et al. (2014). megaTALs: a rare-cleaving nuclease architecture for therapeutic genome engineering. Nucleic Acids Res 42: 2591-2601
155. Wolfs, JM, DaSilva, M, Meister, SE, Wang, X, Schild-Poulter, C and Edgell, DR. (2014). MegaTevs: single-chain dual nucleases for efficient gene disruption. Nucleic Acids Res 42: 8816-8829
156. Beurdeley, M, Bietz, F, Li, J, Thomas, S, Stoddard, T, Juillerat, A, et al. (2013). Compact designer TALENs for efficient genome engineering. Nat Commun 4: 1762
157. Barrangou, R, Fremaux, C, Deveau, H, Richards, M, Boyaval, P, Moineau, S, et al. (2007). CRISPR provides acquired resistance against viruses in prokaryotes. Science 315: 1709-1712
158. Wiedenheft, B, Sternberg, SH and Doudna, JA. (2012). RNA-guided genetic silencing systems in bacteria and archaea. Nature 482: 331-338
159. Horvath, P and Barrangou, R. (2010). CRISPR/Cas, the immune system of bacteria and archaea. Science 327: 167-170
160. Fineran, PC and Charpentier, E. (2012). Memory of viral infections by CRISPR-Cas adaptive immune systems: acquisition of new information. Virology 434: 202-209
161. Hsu, PD, Lander, ES and Zhang, F. (2014). Development and applications of CRISPR-Cas9 for genome engineering. Cell 157: 1262-1278
162. Garneau, JE, Dupuis, MÈ, Villion, M, Romero, DA, Barrangou, R, Boyaval, P, et al. (2010). The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA. Nature 468: 67-71
163. Deltcheva, E, Chylinski, K, Sharma, CM, Gonzales, K, Chao, Y, Pirzada, ZA, et al. (2011). CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III. Nature 471: 602-607
164. Jinek, M, Chylinski, K, Fonfara, I, Hauer, M, Doudna, JA and Charpentier, E. (2012). A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337: 816-821
165. Mali, P, Yang, L, Esvelt, KM, Aach, J, Guell, M, DiCarlo, JE, et al. (2013). RNA-guided human genome engineering via Cas9. Science 339: 823-826
166. Cong, L, Ran, FA, Cox, D, Lin, S, Barretto, R, Habib, N, et al. (2013). Multiplex genome engineering using CRISPR/Cas systems. Science 339: 819-823
167. Jinek, M, East, A, Cheng, A, Lin, S, Ma, E and Doudna, J. (2013). RNA-programmed genome editing in human cells. Elife 2: e00471
168. Cho, SW, Kim, S, Kim, JM and Kim, JS. (2013). Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat Biotechnol 31: 230-232
169. Fonfara, I, Le Rhun, A, Chylinski, K, Makarova, KS, Lécrivain, AL, Bzdrenga, J, et al. (2014). Phylogeny of Cas9 determines functional exchangeability of dual-RNA and Cas9 among orthologous type II CRISPR-Cas systems. Nucleic Acids Res 42: 2577-2590
170. Chylinski, K, Makarova, KS, Charpentier, E and Koonin, EV. (2014). Classification and evolution of type II CRISPR-Cas systems. Nucleic Acids Res 42: 6091-6105
171. Sternberg, SH, Redding, S, Jinek, M, Greene, EC and Doudna, JA. (2014). DNA interrogation by the CRISPR RNA-guided endonuclease Cas9. Nature 507: 62-67
172. Kleinstiver, BP, Prew, MS, Tsai, SQ, Topkar, VV, Nguyen, NT, Zheng, Z, et al. (2015). Engineered CRISPR-Cas9 nucleases with altered PAM specificities. Nature 523: 481-485
173. Kleinstiver, BP, Prew, MS, Tsai, SQ, Nguyen, NT, Topkar, VV, Zheng, Z, et al. (2015). Broadening the targeting range of Staphylococcus aureus CRISPR-Cas9 by modifying PAM recognition. Nat Biotechnol 33: 1293-1298
174. Jinek, M, Jiang, F, Taylor, DW, Sternberg, SH, Kaya, E, Ma, E, et al. (2014). Structures of Cas9 endonucleases reveal RNA-mediated conformational activation. Science 343: 1247997
175. Anders, C, Niewoehner, O, Duerst, A and Jinek, M. (2014). Structural basis of PAMdependent target DNA recognition by the Cas9 endonuclease. Nature 513: 569-573
176. Nishimasu, H, Ran, FA, Hsu, PD, Konermann, S, Shehata, SI, Dohmae, N, et al. (2014). Crystal structure of Cas9 in complex with guide RNA and target DNA. Cell 156: 935-949
177. Josephs, EA, Kocak, DD, Fitzgibbon, CJ, McMenemy, J, Gersbach, CA and Marszalek, PE. (2015). Structure and specificity of the RNA-guided endonuclease Cas9 during DNA interrogation, target binding and cleavage. Nucleic Acids Res 43: 8924-8941
178. Zetsche, B, Gootenberg, JS, Abudayyeh, OO, Slaymaker, IM, Makarova, KS, Essletzbichler, P, et al. (2015). Cpf1 Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas System. Cell 163: 759-771
179. Shmakov, S, Abudayyeh, OO, Makarova, KS, Wolf, YI, Gootenberg, JS, Semenova, E, et al. (2015). Discovery and Functional Characterization of Diverse Class 2 CRISPR-Cas Systems. Mol Cell 60: 385-397
180. Szczepek, M, Brondani, V, Büchel, J, Serrano, L, Segal, DJ and Cathomen, T. (2007). Structure-based redesign of the dimerization interface reduces the toxicity of zincfinger nucleases. Nat Biotechnol 25: 786-793
181. Miller, JC, Holmes, MC, Wang, J, Guschin, DY, Lee, YL, Rupniewski, I, et al. (2007). An improved zinc-finger nuclease architecture for highly specific genome editing. Nat Biotechnol 25: 778-785
182. Doyon, JB, Zeitler, B, Cheng, J, Cheng, AT, Cherone, JM, Santiago, Y, et al. (2011). Rapid and efficient clathrin-mediated endocytosis revealed in genome-edited mammalian cells. Nat Cell Biol 13: 331-337
183. Guo, J, Gaj, T and Barbas, CF 3rd. (2010). Directed evolution of an enhanced and highly efficient FokI cleavage domain for zinc finger nucleases. J Mol Biol 400: 96-107
184. Ran, FA, Hsu, PD, Lin, CY, Gootenberg, JS, Konermann, S, Trevino, AE, et al. (2013). Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell 154: 1380-1389
185. Mali, P, Aach, J, Stranges, PB, Esvelt, KM, Moosburner, M, Kosuri, S, et al. (2013). CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nat Biotechnol 31: 833-838
186. Tsai, SQ, Wyvekens, N, Khayter, C, Foden, JA, Thapar, V, Reyon, D, et al. (2014). Dimeric CRISPR RNA-guided FokI nucleases for highly specific genome editing. Nat Biotechnol 32: 569-576
187. Guilinger, JP, Thompson, DB and Liu, DR. (2014). Fusion of catalytically inactive Cas9 to FokI nuclease improves the specificity of genome modification. Nat Biotechnol 32: 577-582
188. Fu, Y, Sander, JD, Reyon, D, Cascio, VM and Joung, JK. (2014). Improving CRISPR-Cas nuclease specificity using truncated guide RNAs. Nat Biotechnol 32: 279-284
189. Slaymaker, IM, Gao, L, Zetsche, B, Scott, DA, Yan, WX and Zhang, F. (2016). Rationally engineered Cas9 nucleases with improved specificity. Science 351: 84-88
190. Kleinstiver, BP, Pattanayak, V, Prew, MS, Tsai, SQ, Nguyen, NT, Zheng, Z, et al. (2016). High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-Target effects. Nature 529(7587): 490-495
191. Fu, Y, Foden, JA, Khayter, C, Maeder, ML, Reyon, D, Joung, JK, et al. (2013). High-frequency off-Target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat Biotechnol 31: 822-826
192. Hsu, PD, Scott, DA, Weinstein, JA, Ran, FA, Konermann, S, Agarwala, V, et al. (2013). DNA targeting specificity of RNA-guided Cas9 nucleases. Nat Biotechnol 31: 827-832
193. Pattanayak, V, Lin, S, Guilinger, JP, Ma, E, Doudna, JA and Liu, DR. (2013). Highthroughput profiling of off-Target DNA cleavage reveals RNA-programmed Cas9 nuclease specificity. Nat Biotechnol 31: 839-843
194. Pattanayak, V, Ramirez, CL, Joung, JK and Liu, DR. (2011). Revealing off-Target cleavage specificities of zinc-finger nucleases by in vitro selection. Nat Methods 8: 765-770
195. Gabriel, R, Lombardo, A, Arens, A, Miller, JC, Genovese, P, Kaeppel, C, et al. (2011). An unbiased genome-wide analysis of zinc-finger nuclease specificity. Nat Biotechnol 29: 816-823
196. Sander, JD, Ramirez, CL, Linder, SJ, Pattanayak, V, Shoresh, N, Ku, M, et al. (2013). In silico abstraction of zinc finger nuclease cleavage profiles reveals an expanded landscape of off-Target sites. Nucleic Acids Res 41: e181
197. Veres, A, Gosis, BS, Ding, Q, Collins, R, Ragavendran, A, Brand, H, et al. (2014). Low incidence of off-Target mutations in individual CRISPR-Cas9 and TALEN targeted human stem cell clones detected by whole-genome sequencing. Cell Stem Cell 15: 27-30
198. Smith, C, Gore, A, Yan, W, Abalde-Atristain, L, Li, Z, He, C, et al. (2014). Wholegenome sequencing analysis reveals high specificity of CRISPR/Cas9 and TALEN-based genome editing in human iPSCs. Cell Stem Cell 15: 12-13
199. Kiskinis, E, Sandoe, J, Williams, LA, Boulting, GL, Moccia, R, Wainger, BJ, et al. (2014). Pathways disrupted in human ALS motor neurons identified through genetic correction of mutant SOD1. Cell Stem Cell 14: 781-795
200. Wu, X, Scott, DA, Kriz, AJ, Chiu, AC, Hsu, PD, Dadon, DB, et al. (2014). Genome-wide binding of the CRISPR endonuclease Cas9 in mammalian cells. Nat Biotechnol 32: 670-676
201. Kuscu, C, Arslan, S, Singh, R, Thorpe, J and Adli, M. (2014). Genome-wide analysis reveals characteristics of off-Target sites bound by the Cas9 endonuclease. Nat Biotechnol 32: 677-683
202. Ogeen, H, Henry, IM, Bhakta, MS, Meckler, JF and Segal, DJ. (2015). A genome-wide analysis of Cas9 binding specificity using ChIP-seq and targeted sequence capture. Nucleic Acids Res 43: 3389-3404
203. Tsai, SQ, Zheng, Z, Nguyen, NT, Liebers, M, Topkar, VV, Thapar, V, et al. (2015). GUIDE-seq enables genome-wide profiling of off-Target cleavage by CRISPR-Cas nucleases. Nat Biotechnol 33: 187-197
204. Frock, RL, Hu, J, Meyers, RM, Ho, YJ, Kii, E and Alt, FW. (2015). Genome-wide detection of DNA double-stranded breaks induced by engineered nucleases. Nat Biotechnol 33: 179-186
205. Kim, D, Bae, S, Park, J, Kim, E, Kim, S, Yu, HR, et al. (2015). Digenome-seq: genomewide profiling of CRISPR-Cas9 off-Target effects in human cells. Nat Methods 12: 237-43, 1 p following 243
206. Wang, X, Wang, Y, Wu, X, Wang, J, Wang, Y, Qiu, Z, et al. (2015). Unbiased detection of off-Target cleavage by CRISPR-Cas9 and TALENs using integrase-defective lentiviral vectors. Nat Biotechnol 33: 175-178
207. Hendel, A, Bak, RO, Clark, JT, Kennedy, AB, Ryan, DE, Roy, S, et al. (2015). Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells. Nat Biotechnol 33: 985-989
208. Kim, S, Kim, D, Cho, SW, Kim, J and Kim, JS. (2014). Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins. Genome Res 24: 1012-1019
209. Schumann, K, Lin, S, Boyer, E, Simeonov, DR, Subramaniam, M, Gate, RE, et al. (2015). Generation of knock-in primary human T cells using Cas9 ribonucleoproteins. Proc Natl Acad Sci USA 112: 10437-10442
210. Ramakrishna, S, Kwaku Dad, AB, Beloor, J, Gopalappa, R, Lee, SK and Kim, H. (2014). Gene disruption by cell-penetrating peptide-mediated delivery of Cas9 protein and guide RNA. Genome Res 24: 1020-1027
211. Liu, J, Gaj, T, Patterson, JT, Sirk, SJ and Barbas, CF 3rd. (2014). Cell-penetrating peptide-mediated delivery of TALEN proteins via bioconjugation for genome engineering. PLoS One 9: e85755
212. Gaj, T, Guo, J, Kato, Y, Sirk, SJ and Barbas, CF 3rd. (2012). Targeted gene knockout by direct delivery of zinc-finger nuclease proteins. Nat Methods 9: 805-807
213. Lorden, ER, Levinson, HM and Leong, KW. (2015). Integration of drug, protein and gene delivery systems with regenerative medicine. Drug Deliv Transl Res 5: 168-186
214. Chen, X and Gonçalves, MA. (2015). Engineered viruses as genome editing devices. Mol Ther 24: 447-457
215. Kabadi, AM, Ousterout, DG, Hilton, IB and Gersbach, CA. (2014). Multiplex CRISPR/Cas9-based genome engineering from a single lentiviral vector. Nucleic Acids Res 42: e147
216. Yin, H, Xue, W, Chen, S, Bogorad, RL, Benedetti, E, Grompe, M, et al. (2014). Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat Biotechnol 32: 551-553
217. Bloom, K, Ely, A, Mussolino, C, Cathomen, T and Arbuthnot, P. (2013). Inactivation of hepatitis B virus replication in cultured cells and in vivo with engineered transcription activator-like effector nucleases. Mol Ther 21: 1889-1897
218. Chen, J, Zhang, W, Lin, J, Wang, F, Wu, M, Chen, C, et al. (2014). An efficient antiviral strategy for targeting hepatitis B virus genome using transcription activator-like effector nucleases. Mol Ther 22: 303-311
219. Asokan, A, Schaffer, DV and Samulski, RJ. (2012). The AAV vector toolkit: poised at the clinical crossroads. Mol Ther 20: 699-708
220. Gaj, T, Epstein, BE and Schaffer, DV. (2015). Genome engineering using adenoassociated virus: basic and clinical research applications. Mol Ther. 24: 458-464
221. Russell, DW and Hirata, RK. (1998). Human gene targeting by viral vectors. Nat Genet 18: 325-330
222. Miller, DG, Petek, LM and Russell, DW. (2003). Human gene targeting by adenoassociated virus vectors is enhanced by DNA double-strand breaks. Mol Cell Biol 23: 3550-3557
223. Gellhaus, K, Cornu, TI, Heilbronn, R and Cathomen, T. (2010). Fate of recombinant adeno-Associated viral vector genomes during DNA double-strand break-induced gene targeting in human cells. Hum Gene Ther 21: 543-553
224. Deyle, DR and Russell, DW. (2009). Adeno-Associated virus vector integration. Curr Opin Mol Ther 11: 442-447
225. Lai, Y, Yue, Y, Liu, M, Ghosh, A, Engelhardt, JF, Chamberlain, JS, et al. (2005). Efficient in vivo gene expression by trans-splicing adeno-Associated viral vectors. Nat Biotechnol 23: 1435-1439
226. Ran, FA, Cong, L, Yan, WX, Scott, DA, Gootenberg, JS, Kriz, AJ, et al. (2015). In vivo genome editing using Staphylococcus aureus Cas9. Nature 520: 186-191
227. Friedland, AE, Baral, R, Singhal, P, Loveluck, K, Shen, S, Sanchez, M, et al. (2015). Characterization of Staphylococcus aureus Cas9: a smaller Cas9 for all-in-one adenoassociated virus delivery and paired nickase applications. Genome Biol 16: 257
228. Li, L, Krymskaya, L, Wang, J, Henley, J, Rao, A, Cao, LF, et al. (2013). Genomic editing of the HIV-1 coreceptor CCR5 in adult hematopoietic stem and progenitor cells using zinc finger nucleases. Mol Ther 21: 1259-1269
229. Ye, L, Wang, J, Beyer, AI, Teque, F, Cradick, TJ, Qi, Z, et al. (2014). Seamless modification of wild-Type induced pluripotent stem cells to the natural CCR5Delta32 mutation confers resistance to HIV infection. Proc Natl Acad Sci USA 111: 9591-9596
230. Mandal, PK, Ferreira, LM, Collins, R, Meissner, TB, Boutwell, CL, Friesen, M, et al. (2014). Efficient ablation of genes in human hematopoietic stem and effector cells using CRISPR/Cas9. Cell Stem Cell 15: 643-652
231. Sather, BD, Romano Ibarra, GS, Sommer, K, Curinga, G, Hale, M, Khan, IF, et al. (2015). Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci Transl Med 7: 307ra156
232. Wilen, CB, Wang, J, Tilton, JC, Miller, JC, Kim, KA, Rebar, EJ, et al. (2011). Engineering HIV-resistant human CD4+ T cells with CXCR4-specific zinc-finger nucleases. PLoS Pathog 7: e1002020
233. Badia, R, Pauls, E, Riveira-Munoz, E, Clotet, B, Esté, JA and Ballana, E. (2014). Zinc finger endonuclease targeting PSIP1 inhibits HIV-1 integration. Antimicrob Agents Chemother 58: 4318-4327
234. Fadel, HJ, Morrison, JH, Saenz, DT, Fuchs, JR, Kvaratskhelia, M, Ekker, SC, et al. (2014). TALEN knockout of the PSIP1 gene in human cells: analyses of HIV-1 replication and allosteric integrase inhibitor mechanism. J Virol 88: 9704-9717
235. Voit, RA, McMahon, MA, Sawyer, SL and Porteus, MH. (2013). Generation of an HIV resistant T-cell line by targeted stacking of restriction factors. Mol Ther 21: 786-795
236. Hu, W, Kaminski, R, Yang, F, Zhang, Y, Cosentino, L, Li, F, et al. (2014). RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection. Proc Natl Acad Sci USA 111: 11461-11466
237. Cradick, TJ, Keck, K, Bradshaw, S, Jamieson, AC and McCaffrey, AP. (2010). Zinc-finger nucleases as a novel therapeutic strategy for targeting hepatitis B virus DNAs. Mol Ther 18: 947-954
238. Weber, ND, Stone, D, Sedlak, RH, De Silva Feelixge, HS, Roychoudhury, P, Schiffer, JT, et al. (2014). AAV-mediated delivery of zinc finger nucleases targeting hepatitis B virus inhibits active replication. PLoS One 9: e97579
239. Lin, SR, Yang, HC, Kuo, YT, Liu, CJ, Yang, TY, Sung, KC, et al. (2014). The CRISPR/Cas9 system facilitates clearance of the intrahepatic HBV templates in vivo. Mol Ther Nucleic Acids 3: e186
240. Dong, C, Qu, L, Wang, H, Wei, L, Dong, Y and Xiong, S. (2015). Targeting hepatitis B virus cccDNA by CRISPR/Cas9 nuclease efficiently inhibits viral replication. Antiviral Res 118: 110-117
241. Kennedy, EM, Bassit, LC, Mueller, H, Kornepati, AV, Bogerd, HP, Nie, T, et al. (2015). Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease. Virology 476: 196-205
242. Liu, X, Hao, R, Chen, S, Guo, D and Chen, Y. (2015). Inhibition of hepatitis B virus by the CRISPR/Cas9 system via targeting the conserved regions of the viral genome. J Gen Virol 96: 2252-2261
243. Grosse, S, Huot, N, Mahiet, C, Arnould, S, Barradeau, S, Clerre, DL, et al. (2011). Meganuclease-mediated inhibition of HSV1 infection in cultured cells. Mol Ther 19: 694-702
244. Bi, Y, Sun, L, Gao, D, Ding, C, Li, Z, Li, Y, et al. (2014). High-efficiency targeted editing of large viral genomes by RNA-guided nucleases. PLoS Pathog 10: e1004090
245. Aubert, M, Boyle, NM, Stone, D, Stensland, L, Huang, ML, Magaret, AS, et al. (2014). In vitro inactivation of latent HSV by targeted mutagenesis using an HSV-specific homing endonuclease. Mol Ther Nucleic Acids 3: e146
246. Kennedy, EM, Kornepati, AV, Goldstein, M, Bogerd, HP, Poling, BC, Whisnant, AW, et al. (2014). Inactivation of the human papillomavirus E6 or E7 gene in cervical carcinoma cells by using a bacterial CRISPR/Cas RNA-guided endonuclease. J Virol 88: 11965-11972
247. Couzin-Frankel, J. (2013). Breakthrough of the year 2013. Cancer immunotherapy. Science 342: 1432-1433
248. Miller, JF and Sadelain, M. (2015). The journey from discoveries in fundamental immunology to cancer immunotherapy. Cancer Cell 27: 439-449
249. Provasi, E, Genovese, P, Lombardo, A, Magnani, Z, Liu, PQ, Reik, A, et al. (2012). Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. Nat Med 18: 807-815
250. Torikai, H, Reik, A, Liu, PQ, Zhou, Y, Zhang, L, Maiti, S, et al. (2012). A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-Antigen-receptor and eliminate expression of endogenous TCR. Blood 119: 5697-5705
251. Berdien, B, Mock, U, Atanackovic, D and Fehse, B. (2014). TALEN-mediated editing of endogenous T-cell receptors facilitates efficient reprogramming of T lymphocytes by lentiviral gene transfer. Gene Ther 21: 539-548
252. Torikai, H, Reik, A, Soldner, F, Warren, EH, Yuen, C, Zhou, Y, et al. (2013). Toward eliminating HLA class I expression to generate universal cells from allogeneic donors. Blood 122: 1341-1349
253. Abrahimi, P, Chang, WG, Kluger, MS, Qyang, Y, Tellides, G, Saltzman, WM, et al. (2015). Efficient gene disruption in cultured primary human endothelial cells by CRISPR/Cas9. Circ Res 117: 121-128
254. Beane, JD, Lee, G, Zheng, Z, Mendel, M, Abate-Daga, D, Bharathan, M, et al. (2015). Clinical scale zinc finger nuclease-mediated gene editing of PD-1 in tumor infiltrating lymphocytes for the treatment of metastatic melanoma. Mol Ther 23: 1380-1390
255. Reik, A., Holmes, MC, Zhou, Y, Mendel, M, Liu, P-Q, Lee, G, et al. (2007). Targeted killing of glioblastoma multiforme in vivo by IL-13 zetakine redirected CTLs made glucocorticoid resistant with zinc finger nucleases. Blood 110: 765a
256. Blaese, RM, Culver, KW, Miller, AD, Carter, CS, Fleisher, T, Clerici, M, et al. (1995). T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years. Science 270: 475-480
257. Cavazzana-Calvo, M, Hacein-Bey, S, de Saint Basile, G, Gross, F, Yvon, E, Nusbaum, P, et al. (2000). Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288: 669-672
258. Joglekar, AV, Hollis, RP, Kuftinec, G, Senadheera, S, Chan, R and Kohn, DB. (2013). Integrase-defective lentiviral vectors as a delivery platform for targeted modification of adenosine deaminase locus. Mol Ther 21: 1705-1717
259. Rahman, SH, Kuehle, J, Reimann, C, Mlambo, T, Alzubi, J, Maeder, ML, et al. (2015). Rescue of DNA-PK signaling and T-cell differentiation by targeted genome editing in a PRKDC deficient iPSC disease model. PLoS Genet 11: e1005239
260. Huang, X, Wang, Y, Yan, W, Smith, C, Ye, Z, Wang, J, et al. (2015). Production of genecorrected adult beta globin protein in human erythrocytes differentiated from patient iPSCs after genome editing of the sickle point mutation. Stem Cells 33: 1470-1479
261. Hoban, MD, Cost, GJ, Mendel, MC, Romero, Z, Kaufman, ML, Joglekar, AV, et al. (2015). Correction of the sickle cell disease mutation in human hematopoietic stem/progenitor cells. Blood 125: 2597-2604
262. Rio, P, Baños, R, Lombardo, A, Quintana-Bustamante, O, Alvarez, L, Garate, Z, et al. (2014). Targeted gene therapy and cell reprogramming in Fanconi anemia. EMBO Mol Med 6: 835-848
263. Vierstra, J, Reik, A, Chang, KH, Stehling-Sun, S, Zhou, Y, Hinkley, SJ, et al. (2015). Functional footprinting of regulatory DNA. Nat Methods 12: 927-930
264. Anguela, XM, Sharma, R, Doyon, Y, Miller, JC, Li, H, Haurigot, V, et al. (2013). Robust ZFN-mediated genome editing in adult hemophilic mice. Blood 122: 3283-3287
265. Sharma, R, Anguela, XM, Doyon, Y, Wechsler, T, DeKelver, RC, Sproul, S, et al. (2015). In vivo genome editing of the albumin locus as a platform for protein replacement therapy. Blood 126: 1777-1784
266. Abifadel, M, Varret, M, Rabès, JP, Allard, D, Ouguerram, K, Devillers, M, et al. (2003). Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 34: 154-156
267. Abifadel, M, Elbitar, S, El Khoury, P, Ghaleb, Y, Chémaly, M, Moussalli, ML, et al. (2014). Living the PCSK9 adventure: from the identification of a new gene in familial hypercholesterolemia towards a potential new class of anticholesterol drugs. Curr Atheroscler Rep 16: 439
268. Ding, Q, Strong, A, Patel, KM, Ng, SL, Gosis, BS, Regan, SN, et al. (2014). Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing. Circ Res 115: 488-492
269. Rousseau, J, Chapdelaine, P, Boisvert, S, Almeida, LP, Corbeil, J, Montpetit, A, et al. (2011). Endonucleases: tools to correct the dystrophin gene. J Gene Med 13: 522-537
270. Popplewell, L, Koo, T, Leclerc, X, Duclert, A, Mamchaoui, K, Gouble, A, et al. (2013). Gene correction of a duchenne muscular dystrophy mutation by meganucleaseenhanced exon knock-in. Hum Gene Ther 24: 692-701
271. Xu, L, Park, KH, Zhao, L, Xu, J, El Refaey, M, Gao, Y, et al. (2015). CRISPR-mediated genome editing restores dystrophin expression and function in mdx mice. Mol Ther 24: 564-569
272. Benabdallah, BF, Duval, A, Rousseau, J, Chapdelaine, P, Holmes, MC, Haddad, E, et al. (2013). Targeted gene addition of microdystrophin in mice skeletal muscle via human myoblast transplantation. Mol Ther Nucleic Acids 2: e68
273. Darabi, R, Arpke, RW, Irion, S, Dimos, JT, Grskovic, M, Kyba, M, et al. (2012). Human ES- and iPS-derived myogenic progenitors restore DYSTROPHIN and improve contractility upon transplantation in dystrophic mice. Cell Stem Cell 10: 610-619
274. Perdoni, C, Osborn, MJ and Tolar, J. (2016). Gene editing toward the use of autologous therapies in recessive dystrophic epidermolysis bullosa. Transl Res 168: 50-58
275. Osborn, MJ, Starker, CG, McElroy, AN, Webber, BR, Riddle, MJ, Xia, L, et al. (2013). TALEN-based gene correction for epidermolysis bullosa. Mol Ther 21: 1151-1159
276. Sebastiano, V, Zhen, HH, Haddad, B, Derafshi, BH, Bashkirova, E, Melo, SP, et al. (2014). Human COL7A1-corrected induced pluripotent stem cells for the treatment of recessive dystrophic epidermolysis bullosa. Sci Transl Med 6: 264ra163
277. Bainbridge, JW, Smith, AJ, Barker, SS, Robbie, S, Henderson, R, Balaggan, K, et al. (2008). Effect of gene therapy on visual function in Lebers congenital amaurosis. N Engl J Med 358: 2231-2239
278. Maguire, AM, Simonelli, F, Pierce, EA, Pugh, EN Jr, Mingozzi, F, Bennicelli, J, et al. (2008). Safety and efficacy of gene transfer for Lebers congenital amaurosis. N Engl J Med 358: 2240-2248
279. Cideciyan, AV, Aleman, TS, Boye, SL, Schwartz, SB, Kaushal, S, Roman, AJ, et al. (2008). Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. Proc Natl Acad Sci USA 105: 15112-15117
280. Hauswirth, WW, Aleman, TS, Kaushal, S, Cideciyan, AV, Schwartz, SB, Wang, L, et al. (2008). Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-Associated virus gene vector: short-Term results of a phase I trial. Hum Gene Ther 19: 979-990
281. Chacon-Camacho, OF and Zenteno, JC. (2015). Review and update on the molecular basis of Leber congenital amaurosis. World J Clin Cases 3: 112-124
282. Burnight, ER, Wiley, LA, Drack, AV, Braun, TA, Anfinson, KR, Kaalberg, EE, et al. (2014). CEP290 gene transfer rescues Leber congenital amaurosis cellular phenotype. Gene Ther 21: 662-672
283. Maeder, M.L., et al. Therapeutic Correction of an LCA-Causing Splice Defect in the CEP290 Gene by CRISPR/Cas-Mediated Genome Editing. Mol Ther 23, S273-S274 (2015
284. Crane, AM, Kramer, P, Bui, JH, Chung, WJ, Li, XS, Gonzalez-Garay, ML, et al. (2015). Targeted correction and restored function of the CFTR gene in cystic fibrosis induced pluripotent stem cells. Stem Cell Reports 4: 569-577
285. Firth, AL, Menon, T, Parker, GS, Qualls, SJ, Lewis, BM, Ke, E, et al. (2015). Functional Gene Correction for Cystic Fibrosis in Lung Epithelial Cells Generated from Patient iPSCs. Cell Rep 12: 1385-1390
286. McNeer, NA, Anandalingam, K, Fields, RJ, Caputo, C, Kopic, S, Gupta, A, et al. (2015). Nanoparticles that deliver triplex-forming peptide nucleic acid molecules correct F508del CFTR in airway epithelium. Nat Commun 6: 6952
287. Bikard, D, Euler, CW, Jiang, W, Nussenzweig, PM, Goldberg, GW, Duportet, X, et al. (2014). Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials. Nat Biotechnol 32: 1146-1150
288. Citorik, RJ, Mimee, M and Lu, TK. (2014). Sequence-specific antimicrobials using efficiently delivered RNA-guided nucleases. Nat Biotechnol 32: 1141-1145
289. Gomaa, AA, Klumpe, HE, Luo, ML, Selle, K, Barrangou, R and Beisel, CL. (2014). Programmable removal of bacterial strains by use of genome-Targeting CRISPR-Cas systems. MBio 5: e00928-e00913
290. Sinkunas, T, Gasiunas, G, Fremaux, C, Barrangou, R, Horvath, P and Siksnys, V. (2011). Cas3 is a single-stranded DNA nuclease and ATP-dependent helicase in the CRISPR/Cas immune system. EMBO J 30: 1335-1342
291. Makarova, KS, Wolf, YI, Alkhnbashi, OS, Costa, F, Shah, SA, Saunders, SJ, et al. (2015). An updated evolutionary classification of CRISPR-Cas systems. Nat Rev Microbiol 13: 722-736
292. Lu, TK and Koeris, MS. (2011). The next generation of bacteriophage therapy. Curr Opin Microbiol 14: 524-531
293. Gaj, T, Sirk, SJ and Barbas, CF 3rd. (2014). Expanding the scope of site-specific recombinases for genetic and metabolic engineering. Biotechnol Bioeng 111: 1-15
294. Swarts, DC, Jore, MM, Westra, ER, Zhu, Y, Janssen, JH, Snijders, AP, et al. (2014). DNAguided DNA interference by a prokaryotic Argonaute. Nature 507: 258-261
295. Hilton, IB and Gersbach, CA. (2015). Enabling functional genomics with genome engineering. Genome Res 25: 1442-1455
296. Keung, AJ, Joung, JK, Khalil, AS and Collins, JJ. (2015). Chromatin regulation at the frontier of synthetic biology. Nat Rev Genet 16: 159-171
297. Thakore, PI, Black, JB, Hilton, IB and Gersbach, CA. (2016). Editing the epigenome: technologies for programmable transcription and epigenetic modulation. Nat Methods 13(2): 127-137